Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel. (Q38164112)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Laurentius A Lesmana

11

object named as

Laurentius A Lesmana

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Ronnie T P Poon

14

object named as

Ronnie T Poon

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

7

object named as

Kwang-Hyub Han

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

18

object named as

Joong-Won Park

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Deepak Amarapurkar

2

object named as

Deepak Amarapurkar

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

3

object named as

Yee Chao

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

9

object named as

Han Chu Lee

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Rheun-Chuan Lee

10

object named as

Rheun-Chuan Lee

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Seung Woon Paik

13

object named as

Seung Woon Paik

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

15

object named as

Chee-Kiat Tan

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Tawesak Tanwandee

16

object named as

Tawesak Tanwandee

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

17

object named as

Gaojun Teng

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Jean-François Geschwind

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Khean L Goh

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Ho Yeong Lim

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

20 November 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Liver International

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

34

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

174-183

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24251922%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Prognosis of hepatocellular carcinoma: the BCLC staging classification

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Management of hepatocellular carcinoma: An update

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009).

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Relationship between serum progesterone concentrations and cardiovascular disease, diabetes, and mortality in elderly Swedish men and women: An 8-year prospective study

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Major achievements in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

RECIST revisited: a review of validation studies on tumour assessment

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Chemoembolization for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Transcatheter arterial chemoembolization: current technique and future promise.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Angiogenesis in cancer and other diseases

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

BAY 43-9006: preclinical data

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

BAY 43-9006 inhibition of oncogenic RET mutants

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand"

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Increased Expression of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12314

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38164112&oldid=1741936789"